140 related articles for article (PubMed ID: 31603947)
1. Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis.
Darbà J
PLoS One; 2019; 14(10):e0223772. PubMed ID: 31603947
[TBL] [Abstract][Full Text] [Related]
2. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
Darbà J
Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
[TBL] [Abstract][Full Text] [Related]
3. Characteristics, comorbidities, and use of healthcare resources of patients with phenylketonuria: a population-based study.
Darbà J
J Med Econ; 2019 Oct; 22(10):1025-1029. PubMed ID: 31237171
[No Abstract] [Full Text] [Related]
4. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.
Darbà J; Marsà A
BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879
[TBL] [Abstract][Full Text] [Related]
5. Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999-2008.
Tsai CP; Wang KC; Hwang CS; Lee IT; Lee CT
J Formos Med Assoc; 2015 Jul; 114(7):612-9. PubMed ID: 26154753
[TBL] [Abstract][Full Text] [Related]
6. Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study.
Jennum P; Ibsen R; Pedersen SW; Kjellberg J
J Neurol; 2013 Mar; 260(3):785-93. PubMed ID: 23104122
[TBL] [Abstract][Full Text] [Related]
7. Direct health costs of amyotrophic lateral sclerosis in a multidisciplinary ALS unit in Catalonia (Spain).
Mora T; Domínguez R; Assialioui A; Paipa A; Moreno R; Corbella X; Martínez-Yelamos A; Povedano M
Amyotroph Lateral Scler Frontotemporal Degener; 2023 Feb; 24(1-2):133-138. PubMed ID: 35670332
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses.
Gladman M; Dharamshi C; Zinman L
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):426-32. PubMed ID: 25025935
[TBL] [Abstract][Full Text] [Related]
9. Impact on healthcare resource utilization of multiple sclerosis in Spain.
Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008-2015.
Cohen B; Balcells C; Hotchkiss B; Aggarwal K; Karaa A
Orphanet J Rare Dis; 2018 Nov; 13(1):210. PubMed ID: 30466460
[TBL] [Abstract][Full Text] [Related]
11. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population- based study of consultations, interventions and costs.
Galvin M; Ryan P; Maguire S; Heverin M; Madden C; Vajda A; Normand C; Hardiman O
PLoS One; 2017; 12(6):e0179796. PubMed ID: 28640860
[TBL] [Abstract][Full Text] [Related]
12. Report by the Spanish Foundation for the Brain on the social impact of amyotrophic lateral sclerosis and other neuromuscular disorders.
Camacho A; Esteban J; Paradas C
Neurologia (Engl Ed); 2018; 33(1):35-46. PubMed ID: 25825074
[TBL] [Abstract][Full Text] [Related]
13. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective.
Connolly S; Heslin C; Mays I; Corr B; Normand C; Hardiman O
Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):58-62. PubMed ID: 25285902
[TBL] [Abstract][Full Text] [Related]
14. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain.
López-Bastida J; Perestelo-Pérez L; Montón-Alvarez F; Serrano-Aguilar P; Alfonso-Sanchez JL
Amyotroph Lateral Scler; 2009 Aug; 10(4):237-43. PubMed ID: 18821088
[TBL] [Abstract][Full Text] [Related]
15. Financial cost of amyotrophic lateral sclerosis: a case study.
Obermann M; Lyon M
Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):54-7. PubMed ID: 25245119
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes.
Lechtzin N; Wiener CM; Clawson L; Chaudhry V; Diette GB
Neurology; 2001 Mar; 56(6):753-7. PubMed ID: 11274310
[TBL] [Abstract][Full Text] [Related]
17. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities.
Chiò A; Bottacchi E; Buffa C; Mutani R; Mora G;
J Neurol Neurosurg Psychiatry; 2006 Aug; 77(8):948-50. PubMed ID: 16614011
[TBL] [Abstract][Full Text] [Related]
18. The economic impact of amyotrophic lateral sclerosis: a systematic review.
Gladman M; Zinman L
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):439-50. PubMed ID: 25924979
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters.
Boylan K; Levine T; Lomen-Hoerth C; Lyon M; Maginnis K; Callas P; Gaspari C; Tandan R;
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 17(1-2):119-27. PubMed ID: 26462131
[TBL] [Abstract][Full Text] [Related]
20. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system.
Oh J; An JW; Oh SI; Oh KW; Kim JA; Lee JS; Kim SH
Amyotroph Lateral Scler Frontotemporal Degener; 2015 Jun; 16(3-4):202-8. PubMed ID: 25646865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
